The pharmacokinetics of hexobarbitone were investigated in 22 patients in an intensive care unit. The results were compared with those obtained in a healthy group for three time periods: 3rd or 4th day (I), 5-8th days (II) and 13-29th days (III) of treatment. Hexobarbitone 7.32 mg per kg of body weight was administered by i.v. infusion in 60 min. At the end of the infusion, the mean plasma concentration of group I was 71% greater than control group; groups II and III were near to control. In all patients the post-infusion concentration-time course of hexobarbitone could be described by two-compartment kinetics. The biphasic decrease in plasma concentration of hexobarbitone was more rapid in groups 11 and III, than in either the control group or in group I. At the beginning of treatment patients generally showed an unchanged hexobarbitone half-life, a slightly decreased plasma clearance, a reduction of approximately 50% of the initial distribution volume (F,) and a reduction of 44% of the distribution volume at steady state. In groups II and III the mean of these values were comparable to control. However, plasma clearance had increased by about 87% in group II compared with control, and after 2-3 weeks (group III) by about 143%. Correspondingly, half-life was reduced by 45% and 58% respectively. The pharmacokinetics were not related to change in liver function. The presence of clinical and bacteriological signs of septicaemia was closely associated with an enhanced hexobarbitone clearance.
. Furthermore, in such patients, even in the absence of cardiac disease, the size of the liver increases rapidly by an average of almost 100% during the 1st week of treatment (Rietbrock and Lazarus, 1979) . This enlargement of the liver is a genuine hypertrophy and reflects mainly an increase in cytoplasmic volume. The meaning of the alterations in serum y-GT and liver growth are open to various interpretations (Schmidt and Schmidt, 1973; Whitfield et al.j 1973; Davidson, Mclntosh and Ford, 1974; Goldberg and Martin, 1975; Hildebrandt et al., 1975; Rietbrock and Lazarus, 1979) .
The purpose of the present investigation in patients with respiratory disturbances and in an intensive care unit was to study the effects of the multiple administrations of drugs on the pharmacokinetics of hexobarbitone at different times during the period of artificial ventilation. Hexobarbitone is completely metabolized in the liver by microsomal enzymes and was chosen, therefore, as a model substance. Its pharmacokinetics are not influenced by protein binding and it is used widely as an indicator of changes in drug metabolizing activity (Bush and Weller, 1972) . It can be used therapeutically in patients during mechanical ventilation to maintain sedation. Numerous reports are available about the changes of hexobarbi-tone disposition in healthy volunteers and in patients with liver disease with normal, enhanced or impaired drug clearance (Breimer et al., 1975; Breimer, Zilly and Richter, 1975; Zilly, Breimer and Richter, 1977; .
PATIENTS AND METHODS

Patients
T h e investigations were carried out in a total of 22 patients in an intensive-care unit (16 males and six females, aged 19-75 yr: average weight 77 28 kg). They had developed various forms of respiratory failure and the lungs were being ventilated artificially. Diagnostic and clinical details of all patients are given in tables I and 11. From their clinical signs and bacteriological data 11 patients were assumed to be septicaemic.
T h e drug therapy is listed in table 111. T h e patients received i.v. alimentation using high calorie solutions.
T h e patients were divided retrospectively into three groups according to the time that had elapsed since the beginning of the intensive-care treatment: group I (n = 7) was examined on the 3rd or 4th day, group I1 (n = 9) between days 5 and 8 and group I11 (n = 6) between days 13 and 29. Investigations were also carried out in a control group of 13 healthy volunteers with normal blood chemical values who had given informed consent.
Hexobarbitone dose and blood sampling
Racemic hexobarbitone sodium (EvipanBayer, Leverkusen, W. Germany) was administered by i.v. infusion in a dose of 7.32 mg kg-' saline 10 mg ml-'. T h e slow infusion was preferred to avoid the possibility of unwanted pharmacological effects. The healthy volunteers had taken no drugs for 4 weeks and had fasted overnight before the investigation. In the intensive care patients any sedative medication, needed to control ventilation, was stopped and the hexobarbitone infusion was started when the patients required further sedation. During the infusion no supplementary sedatives were given. All drugs and the parenteral nutrition were discontinued for 2-4 h after the infusion of hexobarbitone. T h e majority of blood samples were collected in the first 12 h following infusion (1, 15,30 min and 1, 2, 4, 6, 8, 10 h) . In some patients in whom there was a prolonged sedative effect, collection was continued for more than 24 h.
Measurement of hexobarbitone concentration. Plasma samples for the hexobarbitone assay were stored at -15 " C in glass tubes until assayed. T h e plasma concentrations of hexobarbitone were determined by gas chromatography with nitrogen selective detection as described previously by Breimer and van Rossum (1974) .
Curve fitting and calculation of pharmacokinetic parameters. Pharmacokinetic parameters were determined using a two-compartment model. Calculation of the two slopes by non-linear least square regression gave the best fit:
-A , .e-"*+A .e-"* cp(pOs1, -2 where C,,,,,, is the plasma concentration after infusion; A K and A 2 are the coefficients (concentration intercepts of the exponential terms at t* = 0; a and (3 are the rate constants (reciprocal time constants) and t* is the time after the end of the infusion, that is t* = t-T, T being the infusion time. Because of the 60-min infusion time the hypothetical concentration intercepts of the exponential terms with the ordinate were corrected for an i.v. bolus injection of the same amount of drug as described by Loo and Riegelman (1970) :
The pharmacokinetic parameters of the model were calculated according to van Rossum (1971) . The following symbols are used:
(min) = half-lives of the two phases (7^ = 0.69/a; 7/= 0.69/0) F, (litre) = volume of the initial dilution space (central compartment) F" s (litre) = volume of distribution at steady state Cl (ml min" ') = plasma clearance The Student t test or the Wilcoxon/ Mann-Whitney test for comparison of the groups were used for statistical evaluation of the pharmacokinetic data and the routine laboratory tests. The Fisher-Yates test was used to evaluate the influence of the duration of intensive care treatment and of the diseases with and without clinical and bacteriological signs of septicaemia on the plasma clearance of hexobarbitone (Sachs, 1978) .
RESULTS
The three groups of intensive care patients did not differ in regard to sex, age and body weight, diagnosis or final outcome. However, the frequency of bacteriological and clinical signs indicating septicaemia was greater in groups II and III than in group I (P<0.1; table I). There were no significant differences in renal function, albumin content, factor V and glutamic pyruvic transaminase (SGPT) activities between the three groups at the time of the study (table II) . Four patients showed a moderate disturbance of renal function and, despite regular infusions of albumin, 16 patients showed decreases in plasma albumin concentration. The patients in groups I and II had significantly greater plasma bilirubin concentrations than patients of group III (P <0.05; table II), which may be explained by blood transfusion during the initial resuscitation. There was a significant increase in the y-glutamyl transpeptidase (Y-GT) activity depending on the duration of the treatment (table II, group I against group II, P <0.05; and group I against group III, P <0.001). Furthermore, the patients with septicaemia showed significantly greater y-GT activities than patients without septicaemia (P<0.05; table II). Liver function tests did not show a significant relationship to the observed hexobarbitone plasma concentrations at the end of the period of infusion or to the calculated hexobarbitone plasma clearance (table IV) .
The infusion of hexobarbitone to healthy volunteers caused typical signs of depression of the central nervous system towards the end of the 60 min (drowsiness, incoherent speech and sleep). These signs could not be monitored in the patients who were undergoing controlled ventilation. During the i.v. infusion there was a rapid increase in the hexobarbitone plasma concentration in healthy volunteers and in most of the patients. At the end of the period of infusion the mean plasma concentration of the patients in group I was significantly (P< 0.005) greater by almost 71% compared with the control values, whereas these concentrations in group II and III were similar to those of the control subjects ( fig. 1) . However, the individual variation in each group of patients was high. Coefficients of variation were 17% in volunteers and 46%, 47% and 45% in the patient groups I, II and III, respectively ( fig. 1 ).
In figure 2 the mean post-infusion concentration-time curves of hexobarbitone in volunteers and in the three groups of patients are shown. All curves exhibit two distinct phases on semilogarithmic plots, which indicate that the postinfusion plasma concentration-time curves of hexobarbitone could be described by two-compartment kinetics. The mean plasma concentrations were slightly greater in group I and significantly less in groups II and III, from 2 or 4 h onwards compared with control plasma concentrations ( fig. 2) . Thus the decline of the plasma concentration curve was more rapid in groups II and III than in group I and in control. Table V and a slightly reduced hepatic clearance compared with the healthy volunteers. For this group the distribution volumes of the central compartment and at steady state were decreased significantly by an average of almost 50% (P<0.001) and 44% (P<0.001) respectively ( fig. 3 ). With increasing stay in the intensive care unit (groups II and III) the values for the distribution volumes approached those of the control subjects. In group II there was a significant difference, but in group III this was no longer so ( fig. 3) . During respiratory support a continuous decrease of the half-life of hexobarbitone by an average of almost 45% (P<0.02; group II) and 58% (P<0.005; group III) and a corresponding increase of the plasma clearance of hexobarbitone by an average of almost 87% (P<0.05; group II) and 143% (P<0.02; group III) respectively were observed ( fig. 3) .
Independent of the duration of treatment, patients who showed clinical signs and bacteriological evidence of septicaemia, had a significantly greater plasma clearance (8.02 + 5.78 ml min~ ' per kg body weight) of hexobarbitone than patients without septicaemia (3.50+2.44 ml min" "kg" 1 ; P<0.05; table VI). In table VII patients are sub-divided with respect to the estimated median of hexobarbitone plasma clearance of the whole group (4.5 ml min" ' per kg body weight). The frequency of a plasma clearance equal to or greater than 4.5 ml min"'kg" 1 is greater following septicaemia or a 5-day treatment period than in patients without septic disease and at the beginning of intensive care treatment. Hexobarbitone is completely metabolized by the human liver (Bush and Weller, 1972) and its plasma clearance is the best index of the ability of the liver to biotransform this drug in man (Rowland, Benet and Graham, 1973; Perrier and Gibaldi, 1974; Breimer et al., 1975) . In our patients there existed a considerable differencebetween the patient with the greatest clearance of hexobarbitone (patient 18: 20.61 ml min" ' kg"') and the patient with the least (patient 1: 1.13 ml min" ' kg"'), an 18-fold variation in hexobarbitone metabolizing capacity. Thus, as the plasma clearance of hexobarbitone is normally taken as a direct measure of intrinsic metabolic enzyme activity (Perrier and Gibaldi, 1974) , it is of interest that this is not true in many intensive care patients in whom hexobarbitone may be regarded as a high-clearance drug, like lignocaine and propranolol, when the plasma clearance exceeds 8 ml min" ' kg" ' and is dependent on liver blood flow. In such patients hexobarbitone cannot be a suitable model compound to indicate only intrinsic drug metabolizing activity of the human liver.
There is limited information about the influence of severe and complicated disease, requiring intensive care and multiple drug treatment, on the intrinsic drug metabolizing activity of the liver (Sotaniemi, 1973; Sotaniemi and Huhti, 1974; Rietbrock, 1977; Rietbrock and Richter, 1978) . At the beginning of intensive-care treatment (group I) the clearance of hexobarbitone was diminished slightly. This is in agreement with the decrease in plasma clearance of antipyrine observed in intensive care patients during the first days of therapy (Rietbrock and Richter, 1978) . It is possible that the decrease in Pa o . which is often noticed at this stage, leads to a decrease in oxidative drug metabolizing activity and hence to a decrease in plasma clearance of lipophilic drugs. A significant relationship between the oxygen partial pressure and antipyrine plasma clearance has been established (Cumming, 1976) . Furthermore, the decrease in clearance may be caused by lower cytochrome P 450 content of the liver (Schoene, Fleischmann and Remmer, 1972; von Oldershausen et al., 1973) .
During the course of intensive care treatment a significant increase of the plasma clearance of hexobarbitone was observed, which may have been caused by various factors. First, the metabolism of hexobarbitone may be stimulated by other drugs. Ordinarily, intensive care patients receive an average of 15 different drugs per day during artificial ventilation. In addition, it is becoming common to treat patients with brain damage with high doses of barbiturates. Barbiturates and certain tranquillizers are known to stimulate drug metabolism and it can take some days before this effect becomes noticeable.
Second, there are indications that with an increase in body temperature an increase in the rate of elimination of drugs occurs (Ballard, 1974) . In the present investigation half of the patients had clinical signs and bacteriological evidence of septicaemia, and had a significantly greater plasma clearance of hexobarbitone than the patients without septicaemia. In addition to high body temperature, an increase in hydrocortisone concentration may contribute to enhanced drug metabolism among these patients . In the present study septicaemia was more frequent after than before a 5-day period of treatment and it should be realized that in septicaemia drug consumption is at its greatest.
Even among the group of patients without septicaemia a significant (P<0.05) increase of hexobarbitone plasma clearance in relation to treatment was noticed, indicating that body temperature, hydrocortisone, or antibiotic treatment alone are unable to account for the increase in drug metabolizing activity with time.
Third, an increase in liver size during treatment in the intensive care unit (Rietbrock and Lazarus, 1979) was also noticed in the patients described here. The relative liver wet weight as a percentage of the body weight of patients Nos 1,10,15 and 22, who died between the 9th and 51st days of intensive care treatment, was 4.88, 2.34, 3.25 and 3.19%, body weight respectively (normal weight 2% of body weight).
Accelerated biotransformation in patients in intensive care units has been demonstrated also for tolbutamide, antipyrine, digitoxin and verapamil (Rietbrock and Richter, 1978; Rietbrock and Riemenschneider, 1979; Woodcock et al., 1981) . Similar observations have been made in patients undergoing anaesthesia and surgery (Elfstrom, Johansson and Lindgren, 1976) , in patients following barbiturate and paracetamol overdose (Forrest et al., 1974) , all of whom require intensive care treatment for a short period.
Since an unexplained decrease in plasma clearance can take place acutely in intensive care patients, the possibility of undesirable effects from too low or too high a plasma concentration must be considered, especially for drugs with a low therapeutic index.
The plasma pharmacokinetics of hexobarbitone correlate well with the concentration of the drug in the central nervous system (Richter et al., 1972) . Patients at the beginning of intensive therapy (group I) are known to be particularly sensitive to hypnotic drugs and this corresponds with the greater plasma concentrations of hexobarbitone at the end of the infusion.
During infusion the average plasma concentrations of hexobarbitone were also greater in patients with acute hepatitis and in patients with compensated liver cirrhosis, while patients with decompensated liver cirrhosis, ascites and oesophageal varices exhibited a decrease in plasma concentration in comparison with the controls (Breimer, Zilly and Richter, 1975; Keller, 1976; Zilly, Breimer and Richter, 1978) .
The decrease in the initial volume of distribution (F,) in group I was probably the factor responsible for the decreased tolerance of the c.n.s. to hexobarbitone since the brain as well as the plasma are part of the central compartment (Breimer, Zilly and Richter, 1975) . Furthermore, it is quite striking that, independent of the duration of treatment, both the distribution volumes (K, and V s ) of patients without bacteriological evidence and clinical signs of septicaemia were significantly smaller than those of the healthy volunteers (F,: 0.27±0.09 against 0.56±0.16 litre kg" 1 , P<0.001; V": 0.65+0.21 against 1.22±0.24 litre kg" 1 , P<0.001). The physiological factors responsible for these decreases in distribution volumes are uncertain. A delay in the distribution of the drug into the liver, a smaller circulating blood volume, an increase in sympathetic tone, an increase in peripheral shunting of blood and haemodynamic effects are all factors which may be involved (Thomson et al., 1973; Breimer, Zilly and Richter, 1975; Mather et al., 1975) . On the other hand, patients with septicaemia show on average only a slightly smaller initial distribution volume (F,: 0.39+0.21 litre kg" 1 , P<0.05) and an unchanged distribution volume at steady state (V": 1.05 ±0.5 litre kg" ', n.s.), but it should be realized that in some patients with septicaemia the distribution volume is high.
An increase in distribution volume was observed also for tolbutamide in intensive care patients, possibly as a result of a decreased albumin concentration, and a corresponding decrease in the bound fraction or an increase in the permeability of the blood vessels with extravasation of fluid and albumin (Rietbrock and Richter, 1978 resultados obtenidos se compararon con los de un grupo de individuos sanos, durante tres periodos de riempo, a saber: tercer y cuarto dias (I), quinto y octavo dias (II) y decimotercio y vigesimonoveno dias (III) del tratamiento. Se administraron durante 60 minutos 7.32 mg de hexobarbitona por kg. de peso del paciente, por medio de infusion intravenosa. Al termino de la infusion, la concentracion media de plasma correspondiente al grupo I fue un 71 % superior que la del grupo de control; los grupos II y III obtuvieron un valor similar al del grupo de control. El transcurso de riempo correspondiente a la concentraci6n de hexobarbitona despues de la infusion puede describirse, para todos los pacientes, mediante cineticas de dos compartimientos. La disminucion bifasica de la hexobarbitona en la concentracion del plasma fue mas rapida en los grupos 11 y III que en el grupo I y que en el de control. Al principio del tratamiento, los pacientes mostraron, por lo general, un periodo de vida media de la hexobarbitona inalterado, una eliminacion del plasma ligeramente disminuida, una reduccion del 50%, aproximadamente, del volumen inicial de distribucion (K,) y una reduccion del 44% del volumen de distribucion en el estado estacionario. En los grupos II y III la media de cstos valores se comparo con el grupo de control. No obstante, la diminacion del plasma habia aumentado en un 87%, aproximadamente, en el grupo II en comparacion con el grupo I, y despues de un periodo de 2 a 3 semanas (grupo III) en un 143% aproximadamente. Deesta forma, la vida media se redujo en un 45% y en un 58% respectivamente. Las farmacocineucas no estuvieron reladonada al cambio de funcion del higado. La presencia de signos clinicos y bacteriologicos de sepricemia vinieron intomamente asociados con un incremento en la eliminacion del plasma.
Se investigaron las farmacocinencas dc la hexobarbitona en 22 pacientes situados en salas de cuidados intensivos. Los
